Teikoku Pharma USA, Inc.   Report issue

For profit Phase 2
Founded: San Jose CA United States (1997)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2007
NCT00759330
First Marketed Drug
1999
lidocaine (xylocaine)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TEIKOKU PHARMA USA | Teikoku Pharma USA, Inc.

Active Ingredients

Marketed Drugs (1)

lidocaine (xylocaine) (1999)

Drugs in Phase 2 Trials (4)

Key: Teikoku Pharma USA, Inc. (3) Acquired (1)

dexmedetomidine (precedex) (2 trials)

donepezil (aricept) (1 trial)

flurbiprofen (ansaid) (1 trial)

urea (2 trials)

Drugs in Other Trials (2)

aluminum hydroxide (Gaviscon) (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 2)

Low Back Pain (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6